Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Metastatic, Androgen Independent Prostate Cancer · Prostate Cancer
Primary: Number of Patients Free of Dose Limiting Toxicity — 14 participants
Phase 2 N=66 Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers
Healthy
Primary: Radiographic Densities at Selected Regions in Contrast-enhanced CT Examination by Location (Abdominal Aorta), kVp 80 and Contrast Type (Ioforminol vs Iopamidol)…
Phase 2 N=20 Sulforaphane in Treating Patients With Recurrent Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels — 5 percentage of participants
Phase 2 N=36 RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Phase 2 N=48 Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Response Rates Confirmed With CT or MRI — 64.6 percentage of participants
Phase 2 N=30 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Phase 2 N=83 Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
Phase 2 N=18 Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study
Premature Birth · Brain Injury
Primary: To Find the Dose of Melatonin Required to Achieve Physiological Blood Levels in the Preterm Infants Similar to That of the Mother. — 203.3 pg/ml
Phase 2 N=92 ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Disseminated Neuroblastoma · Recurrent Neuroblastoma
Primary: Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors — 45; 42 days
Phase 2 N=177 A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Overweight · Obesity
Primary: Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable Population — -2.68; -3.30; -6.46 kg — p=0.0004
Phase 2 N=46 Sapropterin as a Treatment for Autistic Disorder
Autistic Disorder
Primary: Clinical Global Impression -- Improvement (CGI-I) Scale — 5; 3 participants — p=<.35
Phase 2 N=22 Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD — 2; 14; 1; 2 participants
Phase 2 N=235 Innovative Interventions for Smoking Cessation
Tobacco Use Disorder
Primary: End of Treatment Abstinence Rate — 19; 18; 19 participants